THERAPY DOSSIER · th-6cacade1020d

LYRM03 (3-amino-2-hydroxy-4-phenyl-valyl-isoleucine), a derivative of ubenimex

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28112185 ↗2017Reported benefit

LYRM03, an ubenimex derivative, attenuates LPS-induced acute lung injury in mice by suppressing the TLR4 signaling pathway.

MouseEndotoxin/LPSC57BL/6MaleIntraperitoneal10 mg/kg in vivo; 100 micromol/L in cultured alveolar macro…After intratracheal lipopolysaccharide challenge, exact interval not stated

Model: Acute lung injury induced by intratracheal injection of lipopolysaccharide at 5 mg/kg

LYRM03 at 10 mg/kg intraperitoneally reduced lipopolysaccharide-induced lung oedema, inflammatory cell infiltration, myeloperoxidase activity, pro-inflammatory cytokine production and iNOS and COX-2 expression, attributed to inhibition of Myd88-dependent TLR4 signalling.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…